StemRIM (4599) Stock Overview

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

4599 Stock Information

Symbol

4599

Address

Saito Bio-IncubatorIbaraki, 567-0085Japan

Founded

Trading hours

Website

https://www.stemrim.com

Country

🇯🇵 Japan

Phone Number

81 72 648 7152

StemRIM (4599) Price Chart

StemRIM Overview: Key Details and Summary

Stock data	2023	Change
Price	$3.10	N/A
Market Cap	$186.07M	N/A
Shares Outstanding	60.06M	1.46%
Employees	45.00	N/A
Shareholder Equity	10.37B	10.27%

Valuation	2023	Change
P/E Ratio	1.15	N/A
P/S Ratio	11.30	N/A
P/B Ratio	0.02	N/A

Growth	2023	Change
Return on Equity	0.0001	N/A

Earnings	2023	Change
Revenue	$16.47M	N/A
Earnings	$1.18M	N/A
EPS	2.69	N/A
Earnings Yield	0.8682	N/A
Operating Margin	0.0606	N/A
Net income margin	0.0716	N/A

Financial Strength	2023	Change
Total Assets	$75.05M	N/A
Total Debt	$3.72K	N/A
Cash on Hand	$71.63M	N/A
Debt to Equity	0.0002	58.36%
Cash to Debt	$19.24K	695.69%
Current Ratio	$47.99	-62.79%